KR20220041782A - 루프롤라이드 아세테이트 조성물 및 유방암 치료에 이용하는 방법 - Google Patents

루프롤라이드 아세테이트 조성물 및 유방암 치료에 이용하는 방법 Download PDF

Info

Publication number
KR20220041782A
KR20220041782A KR1020217042734A KR20217042734A KR20220041782A KR 20220041782 A KR20220041782 A KR 20220041782A KR 1020217042734 A KR1020217042734 A KR 1020217042734A KR 20217042734 A KR20217042734 A KR 20217042734A KR 20220041782 A KR20220041782 A KR 20220041782A
Authority
KR
South Korea
Prior art keywords
leuprolide
extended
subject
release composition
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217042734A
Other languages
English (en)
Korean (ko)
Inventor
존 미들턴
아비나시 난기아
존 아서 맥레인
테리 엘. 모튼
Original Assignee
톨마 인터내셔날 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 톨마 인터내셔날 리미티드 filed Critical 톨마 인터내셔날 리미티드
Publication of KR20220041782A publication Critical patent/KR20220041782A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020217042734A 2019-05-27 2020-05-26 루프롤라이드 아세테이트 조성물 및 유방암 치료에 이용하는 방법 Pending KR20220041782A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
US62/853,153 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
KR20220041782A true KR20220041782A (ko) 2022-04-01

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042734A Pending KR20220041782A (ko) 2019-05-27 2020-05-26 루프롤라이드 아세테이트 조성물 및 유방암 치료에 이용하는 방법

Country Status (17)

Country Link
US (2) US12453754B2 (https=)
EP (1) EP3975990A1 (https=)
JP (1) JP7664855B2 (https=)
KR (1) KR20220041782A (https=)
CN (1) CN114144169A (https=)
AR (1) AR119021A1 (https=)
AU (1) AU2020284587B2 (https=)
BR (1) BR112021023904A2 (https=)
CA (1) CA3141456A1 (https=)
EA (1) EA202193257A1 (https=)
IL (1) IL288503A (https=)
MX (1) MX2021014540A (https=)
PH (1) PH12021552976A1 (https=)
SG (1) SG11202112888RA (https=)
TW (1) TWI757753B (https=)
UY (1) UY38717A (https=)
WO (1) WO2020240417A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
DK3660073T3 (da) * 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Also Published As

Publication number Publication date
WO2020240417A1 (en) 2020-12-03
MX2021014540A (es) 2022-04-12
AR119021A1 (es) 2021-11-17
TW202110472A (zh) 2021-03-16
IL288503A (en) 2022-01-01
TWI757753B (zh) 2022-03-11
SG11202112888RA (en) 2021-12-30
AU2020284587A1 (en) 2022-01-06
UY38717A (es) 2020-11-30
US12453754B2 (en) 2025-10-28
EA202193257A1 (ru) 2022-03-10
PH12021552976A1 (en) 2022-07-04
AU2020284587B2 (en) 2025-09-18
BR112021023904A2 (pt) 2022-02-01
US20220265760A1 (en) 2022-08-25
US20260027176A1 (en) 2026-01-29
JP2022535694A (ja) 2022-08-10
JP7664855B2 (ja) 2025-04-18
EP3975990A1 (en) 2022-04-06
CA3141456A1 (en) 2020-12-03
CN114144169A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
US20260027176A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
Miller et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
RU2270003C2 (ru) Лекарственное средство для лечения солидных опухолей на основе паклитаксела, стабилизированного альбумином
EP3328355B1 (en) Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
EP2656860A1 (en) Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
SK137996A3 (en) Cancer treatment and metastasis prevention
CN111281869B (zh) 褪黑素在制备用于治疗和辅助治疗骨肉瘤的药物中的应用
JP2022168328A (ja) 抗がん療法の増感剤
Begg et al. Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors
EP3746047B1 (en) Injectable composition
CN100464736C (zh) 同载抗代谢药物及其增效剂的抗癌缓释注射剂
Eichler et al. Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study
EA046538B1 (ru) Применение лейпролида для подавления функции яичников у субъекта с гормон-рецептор-положительным раком молочной железы
KR101698003B1 (ko) 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
US11110303B2 (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
CN120361228B (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
JP4020256B2 (ja) 前立腺癌の局所治療剤
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
Flörcken et al. Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in western patients
KR20230149007A (ko) 생리활성물질 전달체
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
CN115350199A (zh) 一种生长因子增生的瘢痕组织的溶解及抑制生长的配方
CN118766885A (zh) 泛酸钙在制备治疗索托雷塞毒副作用的药物中的应用
Orenberg Intralesional chemotherapy with injectable collagen gel formulations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000